Optimizing Rheumatology Availity Integration for Biologic Prior Authorizations

Klivira streamlines rheumatology Availity integration, automating the complex prior authorization workflows for high-cost biologics and advanced therapies. This integration is critical for maintaining efficient revenue cycles and ensuring timely patient access.

Rheumatology practices face a disproportionately high prior authorization burden, driven by expensive biologic and targeted synthetic DMARDs. Managing these PAs efficiently, especially across multiple payers via platforms like Availity Essentials, is paramount for revenue cycle directors and PA coordinators to mitigate delays and denials that impact patient care and practice finances.

The High Stakes of Rheumatology Prior Authorization

Rheumatology prior authorizations are concentrated in biologic and targeted therapies for chronic conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. These advanced agents, including TNF-alpha inhibitors (e.g., adalimumab, etanercept) and JAK inhibitors (e.g., tofacitinib), represent significant costs and require rigorous documentation for approval, making efficient processing via platforms like Availity essential.

Key Prior Authorization Triggers in Rheumatology

**Biologics and Targeted Therapies:** High-cost agents such as Humira, Enbrel, Stelara, Skyrizi, and Rinvoq, along with other TNF-alpha inhibitors and non-TNF biologics.
**JAK Inhibitors:** Requiring specific documentation often related to prior TNF inhibitor failure due to FDA warnings and CMS guidance.
**Infusion Therapy:** For provider-administered biologics like infliximab, often subject to medical benefit PA.
**Advanced Imaging:** MRI for inflammatory arthritis assessment, critical for diagnosis and disease activity monitoring.
**DEXA Scans:** For osteoporosis management, particularly in patients on chronic steroids.

Streamlining Rheumatology PA Workflows via Availity Integration

Availity Essentials serves as a critical multi-payer clearinghouse, connecting rheumatology practices to most major commercial payers for prior authorization submissions. Klivira's deep rheumatology Availity integration automates the submission process, interpreting payer-specific rules and documentation requirements derived from clinical guidelines like those from the American College of Rheumatology (ACR).

Critical Documentation for Rheumatology PAs on Availity

**Diagnosis Documentation:** ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR criteria for RA, CASPAR criteria for PsA).
**Disease Activity Assessment:** Scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
**Prior Conventional DMARD Trial:** Documentation of methotrexate or other csDMARD trials, including response or contraindication.
**Step Therapy Compliance:** Proof of failure for required TNF inhibitors or biosimilar trials before escalating to non-TNF biologics or JAK inhibitors.
**Screening Completion:** TB screening (PPD or IGRA), hepatitis B/C screening, and immunization status prior to immunosuppressive biologic initiation.

Klivira's Intelligent Automation for Rheumatology Availity Integration

Klivira's platform is engineered to navigate the complexities of rheumatology prior authorization. Through robust Availity integration, Klivira applies ACR-guideline-aware policy logic, manages biosimilar substitution routing based on per-payer mandates, and automates periodic re-authorization workflows for chronic treatments. This ensures that submissions via Availity meet specific payer requirements, reducing manual effort and common denial reasons.

Addressing Common Rheumatology PA Denials with Klivira

**Step Therapy Not Completed:** Automated verification of prior agent trials against payer rules.
**Biosimilar Substitution Required:** Intelligent routing to ensure biosimilar first-line requirements are met.
**Disease Activity Not Documented:** Proactive identification of missing DAS28, CDAI, or equivalent scores.
**Conservative-Care Duration Insufficient:** Flagging cases where initial csDMARD trial duration is less than payer-required.
**Screening Documentation Gaps:** Alerts for incomplete TB, hepatitis, or immunization documentation prior to submission.

Frequently asked questions

How does Klivira handle biosimilar substitution requirements within Availity for rheumatology PAs?

Klivira's platform integrates payer-specific biosimilar mandates, automatically routing prior authorization requests through Availity to ensure compliance. This includes distinguishing between brand-to-biosimilar conversions and specific biosimilar requirements within step therapy protocols, minimizing denials related to incorrect drug sequencing.

Can Klivira automate re-authorization for chronic rheumatology treatments submitted via Availity?

Yes, Klivira provides a periodic re-authorization workflow specifically designed for chronic rheumatology treatments like biologics. The system tracks approval expiry dates and prompts for necessary continuous-response documentation, then automatically submits the re-authorization request through Availity, reducing administrative burden.

What EMR data does Klivira leverage for rheumatology Availity integration?

Klivira integrates with EMRs to pull relevant clinical data, including ICD-10 diagnoses, disease activity scores (e.g., DAS28, CDAI), prior conventional DMARD trials, and screening results. This data is then formatted and submitted through Availity, aligning with payer-specific documentation requirements and ACR guidelines.

How does Klivira manage the medical vs. pharmacy benefit split for rheumatology drugs when integrating with Availity?

Klivira intelligently routes prior authorization requests for rheumatology agents based on whether they fall under the medical or pharmacy benefit, a common complexity for biologics that can be self-administered or provider-administered. This ensures the correct benefit side is targeted for submission through Availity, preventing misrouted or delayed PAs.